Be My Little Teddy Bear

https://digitalcommons.library.umaine.edu/mmb-vp/5094/thumbnail.jp

The Heaven Born Banner

https://digitalcommons.library.umaine.edu/mmb-vp/4607/thumbnail.jp

Mark-to-Market Accounting for United States Corporate Pensions: Implementation and Impact

This chapter explores a number of aspects of mark-to-market (MTM) accounting, to better understand the effects of a change in accounting method. Corporate plan sponsors have an ongoing management challenge with defined benefit (DB) pensions. Among the many issues is how to properly account for their associated assets and liabilities, and to provide clarity regarding the plan itself while not diluting transparency into the underlying business performance of the corporate plan sponsors. Traditional generally accepted accounting principles (GAAP) for pensions is an overly complex mechanism, attempting to balance these two often conflicting goals. There is an alternative approach: MTM accounting

Stochastic Optimization of Power System Dynamics for Grid Resilience

When faced with uncertainty regarding potential failure contingencies, prioritizing system resiliency through optimal control of exciter reference voltage and mechanical torque can be arduous due to the scope of potential failure contingencies. Optimal control schemes can be generated through a two-stage stochastic optimization model by anticipating a set of contingencies with associated probabilities of occurrence, followed by the optimal recourse action once the contingency has been realized. The first stage, common across all contingency scenarios, co-optimally positions the grid for the set of possible contingencies. The second stage dynamically assesses the impact of each contingency and allows for emergency control response. By unifying the optimal control scheme prior and post the failure contingency, a singular policy can be constructed to maximize system resiliency

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.

PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model.Materials and methodsA colorectal cancer tumor from a patient previously established in non-transgenic nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice in order to label the tumor stromal cells with GFP. Then labeled tumors were orthotopically implanted into the cecum of nude mice. Mice were randomized into four groups: Group 1, untreated control; group 2, TEM + PAZ; group 3, FOLFOX; group 4, TEM + PAZ plus FOLFOX. Tumor width, length, and mouse body weight were measured weekly. The Fluor Vivo imaging System was used to image the GFP-lableled tumor stromal cells in vivo. H&E staining and immunohistochemical staining were used for histological analysis.ResultsAll three treatments inhibited tumor growth as compared to the untreated control group. The combination of TEM + PAZ + FOLFOX regressed tumor growth significantly more effectively than TEM + PAZ or FOLFOX. Only the combination of TEM + PAZ + FOLFOX group caused a decrease in body weight. PAZ suppressed lymph vessels density in the colorectal cancer PDOX mouse model suggesting inhibition of lymphangiogenesis.ConclusionOur results suggest that the combination of TEM + PAZ + FOLFOX has clinical potential for colorectal cancer patient

Automated Construction Progress and Quality Monitoring for Commercial Buildings with Unmanned Aerial Systems: An Application Study from Switzerland

Unmanned Aerial Systems (UASs), which have become a key tool in remote sensing in recent years, have also rapidly entered the practice of Architecture, Engineering, Construction, and Operations (AECO). This paper presents an application study of a methodology for monitoring construction progress and quality using real-time data from a commercial building during the execution phase and the results of an analysis of the costs and benefits of monitoring construction progress and quality with and without a UAS. The methodology used consists of three parts: (1) automated data collection at the construction site, (2) data processing, in which the collected data are processed to generate the outputs necessary for the data analysis, and (3) data analysis to monitor construction progress and quality. The method is based on the detection of structural elements, combined with four principles: the sectional approach, the calculation of the concrete volume, the height-distance measurement, and the detection of defects by visual comparisons. The cost-benefit analysis considers three cases: monitoring of progress (1) by the construction company using the UAS, (2) by external contractors using the UAS, and (3) by the construction company without using the UAS. We show that the in-house operation of the UAS is associated with medium costs. However, a return on investment can be achieved quickly if the strategy for the operation of the UAS is clearly defined. In summary, the use of a UAS for the automated monitoring of the construction progress and quality of commercial buildings is practicable, which can quickly lead to a return on investment. We also show that there is great potential for further improvements.</p

High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models.

Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of bacteria were delivered to the liver with the two doses, indicating that iPV delivery is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area and fluorescence intensity highly correlated (p&lt;0.0001). iPV treatment was more effective compared to both untreated control and iv treatment (p&lt;0.01 and p&lt;0.05, respectively with iPV treatment with S. typhimurium arresting metastatic growth). There were no significant differences in body weight between all groups. The results of this study suggest that S. typhimurium A1-R administered iPV has potential for peri-operative adjuvant treatment of colon cancer liver metastasis

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).

A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic (PDOX) model. Seven weeks after implantation, PDOX nude mice were divided into the following groups: untreated control (n = 7); gemcitabine (100 mg/kg, i.p., once a week for 2 weeks, n = 7); cobimetinib (5 mg/kg, p.o., 14 consecutive days, n = 7); trametinib (0.3 mg/kg, p.o., 14 consecutive days, n = 7); trabectedin (0.15 mg/kg, i.v., once a week for 2 weeks, n = 7); temozolomide (25 mg/kg, p.o., 14 consecutive days, n = 7); carfilzomib (2 mg/kg, i.v., twice a week for 2 weeks, n = 7); bortezomib (1 mg/kg, i.v., twice a week for 2 weeks, n = 7); MK-1775 (20 mg/kg, p.o., 14 consecutive days, n = 7); BEZ-235 (45 mg/kg, p.o., 14 consecutive days, n = 7); vorinostat (50 mg/kg, i.p., 14 consecutive days, n = 7). Only the MEK inhibitors, cobimetinib and trametinib, regressed tumor growth, and they were more significantly effective than other therapies (p &lt; 0.0001, respectively), thereby demonstrating the precision of the PDOX models of PDAC and its potential for individualizing pancreatic-cancer therapy